Edge Therapeutics, Inc.
↗Princeton, New Jersey, USA
Edge Therapeutics was a clinical-stage biotechnology company originally focused on developing hospital-based therapies for acute, life-threatening neurological conditions. Its lead candidate, EG-1962, was a polymer-based microparticle of nimodipine designed to improve outcomes after brain hemorrhages. However, following a Phase 3 clinical trial failure in 2018, the company underwent a strategic pivot.
In March 2019, Edge Therapeutics completed a reverse merger with PDS Biotechnology Corporation, a privately-held immuno-oncology company. Following the merger, the combined entity assumed the PDS Biotechnology name and shifted its focus entirely to PDS's proprietary Versamune® and Infectimune® T-cell activating platforms. The company is now a late-stage immunotherapy firm developing a pipeline of targeted cancer treatments, particularly for HPV-associated cancers.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$0M (Pre-revenue)
Founded:2009
Ownership:public
Status:merged
FUNDING
Stage:Public
Total Raised:$185M
Investors:Venrock, Sofinnova Investments, Hercules Capital, New Leaf Venture Partners, BioMed Ventures, Franklin Resources, Janus Capital Management
STOCK
Exchange:NASDAQ
Ticker:PDSB
Market Cap:$51.7M
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule (Legacy), Immunotherapy, T-cell Activator, Antibody Drug Conjugate (ADC)
Active Trials:5
Trial Phases:Phase 1: 1 | Phase 2: 3 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Acquired By:PDS Biotechnology Corporation (2019-03-15)
Subsidiaries:PDS Operating Corporation
Key Partnerships:National Cancer Institute (NCI) - CRADA for PDS01ADC and PDS0101, Merck & Co. - Clinical trial collaboration for Keytruda combinations, MD Anderson Cancer Center
COMPETITION
Position:Emerging
Competitors:Inovio Pharmaceuticals, Arcus Biosciences, Aura Biosciences, BriaCell Therapeutics, Moderna (Oncology pipeline)
LEADERSHIP
Key Executives:
Frank Bedu-Addo, Ph.D. - CEO & President
Lars Boesgaard - CFO
Kirk Shepard, M.D. - Chief Medical Officer
Scientific Founders:Frank Bedu-Addo, Ph.D., Gregory P. Conn, Ph.D.
Board Members:Frank Bedu-Addo, Sir Richard Sykes, De Lyle W. Bloomquist, Gregory Freitag, Robert Spiegel
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Edge Therapeutics, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.